INSERM U981, Gustave Roussy, Villejuif, France.
INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.
Cell Death Dis. 2020 Nov 11;11(11):964. doi: 10.1038/s41419-020-03175-5.
By targeting the tumor microenvironment to stimulate antitumor immunity, immunotherapies have revolutionized cancer treatment. However, many patients do not respond initially or develop secondary resistance. Based on the limited resources in the tumor microenvironment and competition between tumor and immune cells, the field of immune metabolism has produced extensive knowledge showing that targeting metabolism could help to modulate antitumor immunity. However, among all the different potentially targetable metabolic pathways, it remains unclear which have more potential to overcome resistance to immune checkpoint inhibitors. Here, we explore metabolic reprogramming in cancer cells, which might inhibit antitumor immunity, and strategies that can be used to favor the antitumor response.
通过针对肿瘤微环境来刺激抗肿瘤免疫,免疫疗法已经彻底改变了癌症治疗。然而,许多患者最初没有反应或产生继发性耐药。基于肿瘤微环境中的有限资源以及肿瘤细胞和免疫细胞之间的竞争,免疫代谢领域产生了广泛的知识,表明靶向代谢有助于调节抗肿瘤免疫。然而,在所有不同的潜在可靶向代谢途径中,尚不清楚哪些途径更有潜力克服免疫检查点抑制剂的耐药性。在这里,我们探讨了可能抑制抗肿瘤免疫的癌细胞代谢重编程,以及可以用来促进抗肿瘤反应的策略。